Michael T Kinsella Selected Research

ropidoxuridine (IPdR)

2/2008	Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2'deoxyribose (IPdR) x 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization.
11/2007	5-iodo-2-pyrimidinone-2'-deoxyribose-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael T Kinsella Research Topics

Disease

3	Neoplasms (Cancer) 01/2013 - 11/2007
1	Rectal Neoplasms (Rectal Cancer) 01/2013
1	Anus Neoplasms (Anal Cancer) 09/2009
1	Weight Loss (Weight Reduction) 02/2008
1	Glioma (Gliomas) 11/2007
1	Body Weight (Weight, Body) 11/2007
1	Glioblastoma (Glioblastoma Multiforme) 11/2007

Drug/Important Bio-Agent (IBA)

2	Fluorouracil (Carac)FDA LinkGeneric 01/2013 - 09/2009
2	ropidoxuridine (IPdR)IBA 02/2008 - 11/2007
1	Messenger RNA (mRNA)IBA 01/2013
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 09/2009
1	Hemoglobins (Hemoglobin)IBA 02/2008

Therapy/Procedure

1	Neoadjuvant Therapy 01/2013
1	Chemoradiotherapy 09/2009
1	Drug Therapy (Chemotherapy) 09/2009